EyePoint Inc (EYPT)

Currency in USD
0.3195
-0.0371(-10.40%)
Closed·
0.3220+0.0025(+0.78%)
·
Advertisement
Trading near 52-week Low
EYPT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.31000.3618
52 wk Range
0.310019.1100
Key Statistics
Prev. Close
0.3195
Open
0.3501
Day's Range
0.31-0.3618
52 wk Range
0.31-19.11
Volume
5.97M
Average Volume (3m)
9.33M
1-Year Change
-97.2242%
Book Value / Share
1.26
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
EYPT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
9.5000
Upside
+2,873.40%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

EyePoint Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

3 Buy
9 Hold
1 Sell
Ratings:
13 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 9.5000
(+2,873.40% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Jones Trading
Hold---Downgrade23/10/2026
Laidlaw
Hold---Downgrade20/10/2026
RBC Capital
Hold1.00+212.99%5.00Maintain20/10/2026
Mizuho
Hold0.50+56.49%-Downgrade20/10/2026
JPMorgan
Sell---Downgrade20/10/2026

EyePoint Inc Earnings Call Summary for Q3/2026

  • EyePoint posted Q3 2026 loss of $1.07/share vs. est. $0.91, while revenue of $756K beat forecast of $232K by 226%; shares fell 8.92% to $0.3248.
  • Company cut 53% of workforce for $30M annual savings; $118M cash expected to fund operations into late Q3 2027 before additional financing needed.
  • Pivoting to DME program after two Phase III wet AMD trials missed primary endpoints; top-line DME results from COMO and CAPRI trials due early Q4 2027.
  • CEO Duker cited encouraging wet AMD secondary data including vision improvement and favorable safety; CFO Elston emphasized multiple levers to extend runway.
  • Over 550 patients enrolled in combined DME trials; management reviewing additional cost cuts and potential financing to reach 2027 readout without cash shortfall.
Last Updated: 12/11/2026, 14:58
Read Full Transcript

Earnings

Latest Release
12/11/2026
EPS / Forecast
-1.07 / -0.91
Revenue / Forecast
756K / 232.15K
EPS Revisions
Last 90 days

Compare EYPT to Peers and Sector

Metrics to compare
EYPT
Peers
Sector
Relationship
P/E Ratio
−0.1x−3.9x−0.2x
PEG Ratio
-−0.160.00
Price/Book
0.3x1.4x2.6x
Price / LTM Sales
10.7x1.9x2.8x
Upside (Analyst Target)
-36.8%63.4%
Fair Value Upside
Unlock15.7%9.5%Unlock

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company’s pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
32.28M37.44%11.51M
Other Institutional Investors
101.05M62.56%36.03M
Public Companies & Retail Investors
0.000.00%0.00
Total
133.33M100.00%47.54M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Janus Henderson Biotech Innovation Master Fund Limited10.86%9,366,3323,340
Janus Henderson Group Ltd.10.86%9,366,3323,340

People Also Watch

0.0255
KPTIQ
+45.71%
0.3259
HRTX
-9.30%
7.700
AVTX
-9.52%
0.5076
WHLR
-32.24%
2.580
BKYI
+4.03%

FAQ

What Is the EyePoint (NASDAQ: EYPT) Share Price Today?

The EyePoint stock price today is 0.3195 USD.

What Stock Exchange Does EyePoint (EYPT) Trade On?

EyePoint is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for EyePoint?

The stock symbol (also called a 'ticker') for EyePoint is "EYPT."

What Is the Current EyePoint Market Capitalisation?

As of today, EyePoint (NASDAQ: EYPT) market cap is 27.5400M USD.

What Is EyePoint's (EYPT) Earnings Per Share (TTM)?

The EyePoint EPS is currently -3.97 (Trailing Twelve Months).

When Is the Next EyePoint Earnings Date?

EyePoint's next earnings report will be released on 04/03/2027.

Is EYPT a Buy or Sell From a Technical Analyst Perspective?

Based on today's EyePoint moving averages and other technical indicators, the daily buy/sell signal for EYPT stock is Strong Sell.

How Many Times Has EyePoint Stock Split?

EyePoint has split 2 times. (See the EYPT stock split history page for full effective split date and price information.)

What is the current trading status of EyePoint (NASDAQ: EYPT)?

As of 13/11/2026, EyePoint (EYPT) is trading at a share price of 0.3195 USD, with a previous close of 0.3195 USD. The stock has fluctuated within a day range of 0.3100 USD to 0.3618 USD, while its 52-week range spans from 0.3100 USD to 19.1100 USD.

What Is EyePoint (EYPT) Price Target According to Analysts?

The average 12-month price target for EyePoint is 9.5000 USD, with a high estimate of 31 USD and a low estimate of 0.5 USD. 3 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Neutral. The stock has an +2,873.40% Upside potential.

What Is the EYPT Premarket Price?

EYPT's last pre-market stock price is 0.3220 USD. The pre-market share volume is 3,800.0000, and the stock has decreased by 0.0025, or 0.7800%.

What Is the EYPT After Hours Price?

EYPT's last after hours stock price is 0.3457 USD, the stock has decreased by 0.0262, or 8.2000%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.